Adrenal Dysfunction Caused by a Critical Condition During Extracorporeal Membrane Oxygenation

ABSTRACT Currently, the assessment of adrenal dysfunction in critically ill patients and ways to correct adrenal dysfunction with hormone replacement therapy are extremely difficult. The results of the Cochrane meta-analysis “Corticosteroids for treating sepsis” showed that survival was higher among patients with respiratory distress syndrome and septic shock who received glucocorticoids (mainly hydrocortisone) for a long course and at low doses. These results are in very good agreement with the concept of critical illness-related corticosteroid insufficiency (CIRCI) development in the subacute and chronic stages of a critical condition and the need to prescribe glucocorticoid replacement therapy in this situation. International guidelines for the treatment of sepsis and septic shock for 2016 suggest avoiding the use of hydrocortisone in patients who developed sepsis. Only the development of septic shock, and the persisting instability of hemodynamics against the background of achieving normovolemia and high doses of vasopressors, are the indication for the use of hydrocortisone 200 mg intravenously. In 2021, revised guidelines approved the administration of hydrocortisone to patients in septic shock without waiting for an adequate fluid loading to be achieved. In contrast to these recommendations, the Society of Critical Care Medicine and the European Society of Intensive Care Medicine, in their recommendations for 2017, suggest for adrenal dysfunction caused by a critical condition in patients with severe community-acquired pneumonia and circulatory arrest the use of hydrocortisone in the early stages, before the development of multiple organ failure. The existing guidelines do not consider the use of hydrocortisone in critical conditions during extracorporeal membrane oxygenation (ECMO). The timing of hydrocortisone administration to critically ill patients requiring ECMO, and the duration of this therapy are currently a topical issue for intensive care specialists. To ensure the completeness of the list of references for compiling a systematic review in the databases MEDLINE, PubMed, MeSH, eLibrary.EN a search was performed for matches, by keywords, and phrases, the roots of keywords, taking into account possible word forms, by the first two hundred relevant links, in case there were so many links. The exclusion criterion was “the use of synthetic glucocorticoids”.

1. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937–1949. PMID: 18496365 https://doi.org/10.1097/ccm.0b013e31817603ba

2.

3. Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM). Crit Care Med. 2017;45(12):2078–2088. PMID: 28938253 https://doi.org/10.1097/CCM.0000000000002737

4.

5. Evdokimova EA, Vlasenko AV, Avdeeva SN. Respiratornaya podderzhka patsientov v kriticheskom sostoyanii. Moscow: GEOTAR-Media Publ.; 2021. (In Russ.).

6.

7. Extracorporeal Life Support Organization (ELSO) General Guidelines for all ECLS Cases. Available at: https://www.elso.org/Portals/0/ELSO%20G uidelines%20General%20All%20ECLS%20Version%201_4.pdf [Accessed Feb 20, 2023].

8.

9. Boonen E, Van den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. J Clin Endocrinol Metab. 2014;99(5):1569–1582. PMID: 24517153 https://doi.org/10.1210/ jc.2013-4115

10.

11. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881– 1893. PMID: 12788587 https://doi.org/10.1016/S0140-6736(03)13492-7

12.

13. Lee MK, Vasikaran S, Doery JC, Wijeratne N, Prentice D. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgrad Med J. 2013;89:617–620. PMID: 23729816 https://doi.org/10.1136/ postgradmedj-2012-131723

14.

15. Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 1992;75:259–264. PMID: 1320051 https://doi. org/10.1210/jcem.75.1.1320051

16.

17. Roux Le CW, Meeran K, Alaghband-Zadeh J. Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment? Ann Clin Biochem. 2002;39(2):148–150. PMID: 11930947 https://doi.org/10 .1258/0004563021901919

18.

19. Meduri GU, Yates CR. Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci. 2004;1024:24–53. PMID: 15265772 https://doi.org/10.1196/annals.1321.004

20.

21. Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamicpituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998;83:2350–2354. PMID: 9661607 https://doi. org/10.1210/jcem.83.7.4980

22.

23. Rehan M, Raizman JE, Cavalier E, Don-Wauchope AC, Holmes DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem. 2015;48:377–387. PMID: 25619896 https://doi. org/10.1016/j.clinbiochem.2015.01.003

24.

25. Fadeev VV, Mel’nichenko GA. Nadpochechnikovaya nedostatochnost’ (klinika, diagnostika, lechenie). Moscow: Medpraktika-M; 2003. (In Russ.).

26.

27. Jenkins D, Forsham PH, Laidlaw JC, Reddy WJ, Thorn GW. Use of ACTH in the diagnosis of adrenal cortical insufficiency. Am J Med. 1955;18:3– 14. PMID: 13218033 https://doi.org/10.1016/0002-9343(55)90200-X

28.

29. Reimondo G, Bovio S, Allasino B, Terzolo M, Angeli A. Secondary hypoadrenalism. Pituitary. 2008;11:147–154. PMID: 18418713 https:// doi.org/10.1007/s11102-008-0108-4

30.

31. Dhillo WS, Kong WM, Le Roux CW, Alaghband-Zadeh J, Jones J, Carter G, et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol. 2002;146:231–235. PMID: 11834433 https://doi.org/10.1530/ eje.0.1460231

32.

33. Combes A, Peek GJ, Hajage D, Hardy P, Abrams D, Schmidt M, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med. 2020;46(11):2048–2057. PMID: 33021684 https://doi.org/10.1007/s00134-020-06248-3

34.

35. Ho JT, Al-Musalhi H, Chapman MJ, Quach T, Thomas PD, Bagley CJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab. 2006;91:105–114. PMID: 16263835 https://doi.org/10.1210/jc.2005-0265

36.

37. Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg. 2005;101:1792–1798. PMID: 16301260. https://doi. org/10.1213/01.ane.0000184042.91452.48

38.

39. Bouachour G, Roy PM, Guiraud MP. The repetitive short corticotropin stimulation test in patients with septic shock. Ann Intern Med. 1995;123:962–963. PMID: 7486498 https://doi.org/10.7326/0003-4819- 123-12-199512150-00018

40.

41. Téblick A, Peeters B, Langouche L, den Berghe GV. Adrenal function and dysfunction in critically ill patients. Nat Rev Endocrinol. 2019;15(7):417– 427. PMID: 30850749 https://doi.org/10.1038/s41574-019-0185-7

42.

43. Berghe GV den, Zegher F de, Veldhuis JD, Wouters P, Gouwy S, Stockman W, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone secretagogues. Clin Endocrinol (Oxf). 1997;47:599–612. PMID: 9425400 https://doi.org/10.1046/j.1365-2265.1997.3371118.x

44.

45. Peeters B, Langouche L, Van den Berghe G. Adrenocortical stress response during the course of critical illness. Compr Physiol. 2017;8(1):283–298. PMID: 29357129 https://doi.org/10.1002/cphy.c170022

46.

47. Nickler M, Ottiger M, Steuer C, Kutz A, Christ-Crain M, Zimmerliet W, et al. Time-dependent association of glucocorticoids with adverse outcome in community-acquired pneumonia: a 6-year prospective cohort study. Critical Care. 2017;21:72. PMID: 28335807 https://doi. org/10.1186/s13054-017-1656-7

48.

49. Schwingshackl A, Meduri GU. Rationale for prolonged glucocorticoid use in pediatric ARDS: what the adults can teach us. Front Pediatr. 2016;4:58. PMID: 27379217 https://doi.org/10.3389/fped.2016.00058

50.

51. Merkulov VM, Merkulova TI. Glucocorticoid Receptor Isoforms Generated by Alternative Splicing and Alternative Translation Initiation. Vavilov Journal of Genetics And Breeding. 2011;15(4):621–632. (In Russ.).

52.

53. Mel’nichenko GA, Troshina EA, Yukina MYu, Platonova NM, Bel’tsevich DG. Klinicheskie rekomendatsii Rossiyskoy Assotsiatsii Endokrinologov (RAE) po diagnostike i lecheniyu pervichnoy nadpochechnikovoy nedostatochnosti u vzroslykh patsientov (proekt). (in Russ.) Available at: https://www.endocrincentr.ru/sites/default/ files/specialists/science/clinic-recomendations/consilium_2017.pdf [Accessed Feb 20, 2023]

54.

55. Gosudarstvennyy reestr lekarstvennykh sredstv. (in Russ.) Available at: https://minzdrav.gov.ru/opendata/7707778246-grls/visual [Accessed Feb 20, 2023]

56.

57. Comparison of systemic glucocorticoid preparations – UpToDate. Available at: https://www.uptodate.com/contents/image?imageKey=ENDO%2F6 4138 [Accessed Feb 20, 2023].

58.

59. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015;12:CD002243. PMID: 31808551 https://doi.org/10.1002/14651858. CD002243.pub4

60.

61. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645–650. PMID: 9559600 https://doi.org/10.1097/00003246-199804000-00010

62.

63. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723–732. PMID: 10321661 https://doi. org/10.1097/00003246-199904000-00025

64.

65. Bone RG, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–658. PMID: 3306374 https://doi.org/10.1056/NEJM198709103171101

66.

67. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138(1):62–68. PMID: 3202402 https://doi.org/10.1164/ajrccm/138.1.62

68.

69. Chawla K, Kupfer Y, Goldman I, Tessler S. Hydrocortisone reverses refractory septic shock. Crit Care Med. 1999;27(1S):A33. https://doi. org/10.1097/00003246-199901001-00022

70.

71. Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–871. PMID: 12186604 https://doi.org/10.1001/ jama.288.7.862

72.

73. Oppert M, Schindler R, Husung C, Offerman K, Graef KJ, Boenisch O, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33:2457–2464. PMID: 16276166 https://doi.org/10.1097/01. ccm.0000186370.78639.23

74.

75. Confalonieri M, Urbino R, Potena A, Piatella M, Parigi P, Giacomo P, et al. Hydrocortisone infusion for severe community acquired pneumonia: apreliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248. PMID: 15557131 https://doi.org/10.1164/ rccm.200406-808OC

76.

77. Tandan SM., Guleria R., Gupta N. Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Am J Respir Crit Care Med. 2005;171: A43.

78.

79. Rinaldi S, Adembri C, Grechi S, de Gaudio R. Low-dose hydrocortisone during severe sepsis: effects on microalbumineria. Crit Care Med. 2006;34:2334–2339. PMID: 16850006 https://doi.org/10.1097/01. CCM.0000233872.04706.BB

80.

81. Cicarelli DD, Vieira JE, Bensenor FEM. Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J. 2007;125(4):237–241. PMID: 17992396 https://doi. org/10.1590/s1516-31802007000400009

82.

83. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159–165. PMID: 9669790 https://doi.org/10.1001/ jama.280.2.159

84.

85. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Medicine. 1984;311(18):1137– 1143. PMID: 6384785 https://doi.org/10.1056/NEJM198411013111801

86.

87. Hu B, Li JG, Liang H, Zhou Q, Yu Z, Li L, et al. The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009;21:529–531. PMID: 19751560 https://doi.org/10.3760/ CMA.J.ISSN.1003-0603.2009.09.006

88.

89. Snijders D, Daniels JM., de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975–982. PMID: 20133929 https://doi.org/10.1164/ rccm.200905-0808OC

90.

91. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010;182:1971–1977. PMID: 21059778 https://doi.org/10.1503/cmaj.090707

92.

93. Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiologic-dose steroid therapy in sepsis. Crit Care. 2002;6(3):251– 259. PMID: 12133187 https://doi.org/10.1186/cc1498

94.

95. Yildiz O, Tanriverdi F, Simsek S, Aygen B, Kelestimur F. The effects of moderate-dose steroid therapy in sepsis: a placebo-controlled, randomized study. J Res Med Sci. 2011;16:1410–1421. PMID: 22973341

96.

97. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double- blind, placebocontrolled trial. Lancet. 2011;377(9782):2023–2030. PMID: 21636122 https://doi.org/10.1016/S0140-6736(11)60607-7

98.

99. Sabry NA, El-Din Omar E. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacology and Pharmacy. 2011;2(2):73–81. https://doi.org/10.4236/pp.2011.22009

100.

101. Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi. 2012;51(8):599–603. PMID: 23158856

102.

103. Rezk NA, Ibrahim AM. Effects of methyl prednisolone in early ARDS. Egypt J Chest Dis Tuberc. 2013;62(1):167–172. https://doi.org/10.1016/ J.EJCDT.2013.02.013

104.

105. Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ. Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open. 2014;4:e005866. PMID: 24993769 https://doi.org/10.1136/bmjopen-2014-005866

106.

107. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community- acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677–686. PMID: 25688779 https://doi.org/10.1001/jama.2015.88

108.

109. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317(11):659–665. PMID: 2888017 https://doi.org/10.1056/NEJM198709103171102

110.

111. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976;184(3):333–341. PMID: 786190 https://doi.org/10.1097/00000658- 197609000-00011

112.

113. Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N England Journal of Medicine. 2008;358(2):111–124. https://doi.org/10.1056/ NEJMoa071366

114.

115. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–518. PMID: 27483065 https://doi. org/10.1001/jama.2016.10485

116.

117. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809–818. PMID: 29490185 https://doi. org/10.1056/NEJMoa1705716

118.

119. Regard S, Butler E, Granholm A, Moller MH, Cohen J, Finfer S, et al. Lowdose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44(7):1003–1016. PMID: 29761216 https://doi.org/10.1007/ s00134-018-5197-6

120.

121. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247. PMID: 34599691 https://doi.org/10.1007/ s00134-021-06506-y

122.

123. Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and metaanalysis. Ann Intern Med. 2015;163(7):519–528. PMID: 26258555 https://doi.org/10.7326/M15-0715

124.

125. Mentzelopoulos SD, Malachias S, Chamos S, Konstantopoulos D, Ntaidou T, Papastylianou A, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest. JAMA. 2013;310(3):270–279. PMID: 23860985 https:// doi.org/10.1177/1751143714564514

126.

127. Tsai MS, Huang CH, Chang WT, Chen WJ, Hsu CY, Hsieh CC, et al. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. Am J Emerg Med. 2007;25(3):318–325. PMID: 17349907 https://doi.org/10.1016/j.ajem.2006.12.007

128.

129. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377. PMID: 2801605 https://doi.org/10.1007/s00134- 017-4683-6

130.

131. Rubartelli A, Lotze MT. Inside, outside, upside down: damageassociated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429–436. PMID: 17845865 https://doi. org/10.1016/j.it.2007.08.004

132.

133. Zindel J, Kubes P. DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation. Annu Rev Pathol. 2020;15:493–518. PMID: 31675482 https://doi.org/10.1146/annurev-pathmechdis-012419-032847

134.

135. Kronenberg GM, Melmed Sh, Polonski KS, Larsen PR. Endokrinologiya po Vil’yamsu. Neyroendokrinologiya. Moscow: GEOTAR-Media Publ.; 2010. (in Russ.).

136.

137. Tuchina OP. Neuro-immune interactions in cholinergic antiinflammatory pathway. Genes & Cells. 2020;15(1):23–28. https:// doi.org/10.23868/202003003

138.

139. Akrout N, Sharshar T, Annane D. Mechanisms of brain signaling during sepsis. Curr Neuropharmacol. 2009;7(4):296–301. PMID: 20514209 https://doi.org/10.2174/157015909790031175

140.

141. Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF, et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20(1):387. PMID: 27890016 https://doi.org/10.1186/s13054-016-1570-4

142.

143. Vanhorebeek I, Langouche L, Berghe den GV. Endocrine aspects of acute and prolonged critical illness. Nat Clin Pract Endocrinol Metab. 2006;2(1):20–31. PMID: 16932250 https://doi.org/10.1038/ ncpendmet0071

144.

145. Deussing J, Chen А. The corticotropin-releasing factor family: physiology of the stress respons. Physiol Rev. 2018;98(4):2225–2286. PMID: 30109816 https://doi.org/10.1152/physrev.00042.2017

146.

147. Crowder CM, Evers AS. Essential drugs in anesthetic practice: Mechanisms of anesthetic action. Anesthetic pharmacology basic principles and clinical practice. 2nd ed. Cambridge University Press; 2011:359–384. https://doi.org/10.1017/CBO9780511781933.025

148.

149. Schmidt RF, Lang F, Heckmann M. (eds). Physiologie Des Menschen: Mit Pathophysiologie. Springer Berlin Heidelberg, 2007 (Rus. Ed.: Shmidt RV, Lang F, Khekmann M (eds.) Fiziologiya cheloveka s osnovami patofiziologii. In 2 vol. Vol. 2. Moscow: Laboratoriya znaniy Publ., 2021)